ResMed Inc. (RMD) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended December 31, 2025 (Q2 of fiscal year 2026). ResMed Inc. is a global leader in medical devices and cloud-based software for diagnosing and treating sleep-disordered breathing and other respiratory disorders. The company operates two primary segments: Sleep and Breathing Health (devices and masks) and Residential Care Software (SaaS platforms for out-of-hospital care).
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Net Revenue | $1,422.8 million | $1,282.1 million | $2,758.4 million | $2,506.6 million |
| Gross Margin | 61.8% | 58.6% | 61.6% | 58.6% |
| Operating Income | $491.7 million | $417.2 million | $938.2 million | $804.6 million |
| Net Income | $392.6 million | $344.6 million | $741.1 million | $656.0 million |
| Diluted EPS | $2.68 | $2.34 | $5.05 | $4.45 |
| Cash & Equivalents | $1,417.1 million | $1,209.5 million (Prior Year End) | N/A | |
| Total Debt (Net) | $663.8 million | $668.3 million (Prior Year End) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 11% year-over-year (YoY) for the quarter and 10% YoY for the six-month period. On a constant currency basis, growth was 9% and 8%, respectively.
- Sleep and Breathing Health: Revenue grew 12% (quarter) and 11% (YTD), driven by increased demand and unit sales for both devices and masks across all regions.
- Residential Care Software: Revenue grew 7% (quarter) and 6% (YTD), with strong growth in the MEDIFOX DAN and Home/Hospice verticals offsetting weaker performance in Senior Living.
- Margin Expansion: Gross margin improved to 61.8% from 58.6% due to manufacturing/logistics efficiencies and component cost improvements.
- Operating Expenses: SG&A increased 15% (quarter) and 12% (YTD), partly due to currency headwinds and costs associated with the VirtuOx acquisition. R&D increased 12% (quarter) and 11% (YTD), primarily due to employee-related costs.
- Restructuring: The company recorded $5.9 million in restructuring charges for the quarter and $21.7 million YTD, related to employee severance and workforce planning. No such expenses were recorded in the prior year periods.
- Interest Income: Net interest income turned positive ($7.9 million for the quarter) compared to a net expense in the prior year, driven by lower debt levels following repayments on the revolving credit facility.
Guidance, Outlook, and Risks
- Outlook: Management expects cash provided by operating activities to fluctuate based on operating results, supply chain conditions, and working capital. The company believes current liquidity sources are sufficient for the next 12 months and beyond.
- Dividends: A quarterly dividend of $0.60 per share was declared for the quarter ended December 31, 2025. A subsequent dividend of $0.60 per share was declared on January 29, 2026, payable March 19, 2026.
- Share Repurchases: The company repurchased $325.0 million of treasury stock during the six months ended December 31, 2025. Approximately 9.6 million shares remain available under the current program.
- Tax Risks: The effective tax rate increased to 20.9% (quarter) and 21.4% (YTD) due to the implementation of global minimum taxes (Pillar Two) and a shift in the global mix of earnings.
- Legal Proceedings:
- NYU Patent Litigation: Dismissed with prejudice in November 2025 after the Federal Circuit affirmed the invalidation of asserted patents.
- Cleveland Medical Litigation: Ongoing patent disputes regarding connected devices and data platforms. Several Inter Partes Review (IPR) proceedings are pending with final decisions expected by July 2026.
- Fractus Litigation: New suit filed in October 2025 alleging infringement of antenna technology patents; IPR proceedings initiated.
- Whistleblower Complaint: An unsealed False Claims Act complaint alleges a conspiracy to overcharge the U.S. Veterans Administration; the company has not been served and cannot estimate potential loss.
Investor Verification Checklist
- Constant Currency Impact: Verify the specific currency headwinds/tailwinds affecting the 2-3% difference between reported and constant currency growth rates.
- Restructuring Run-Rate: Confirm the remaining $6.0 million in restructuring accruals and whether additional charges are anticipated beyond the current plan.
- Debt Covenant Compliance: Review the leverage ratio calculations to ensure continued compliance with the Revolving Credit Agreement and Senior Notes covenants.
- Patent Litigation Timeline: Monitor the July 2026 deadline for final PTAB decisions in the Cleveland Medical IPR proceedings.
- Non-GAAP Reconciliation: Review the reconciliation of Non-GAAP EPS ($2.81) vs. GAAP EPS ($2.68) to understand the impact of amortization and restructuring adjustments.